These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31950229)

  • 1. How conclusive is the CONCLUDE trial?
    Del Prato S
    Diabetologia; 2020 Apr; 63(4):692-697. PubMed ID: 31950229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
    Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
    Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial.
    Evans M; Moes RGJ; Pedersen KS; Gundgaard J; Pieber TR
    Adv Ther; 2020 May; 37(5):2413-2426. PubMed ID: 32306247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
    Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM
    Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
    Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM
    Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design.
    Agesen RM; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen T; Juhl CB; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
    BMC Endocr Disord; 2019 Jul; 19(1):78. PubMed ID: 31337371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
    Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
    Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes.
    Tibaldi J; Hadley-Brown M; Liebl A; Haldrup S; Sandberg V; Wolden ML; Rodbard HW
    Diabetes Obes Metab; 2019 Apr; 21(4):1001-1009. PubMed ID: 30552800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
    Lane W; Bailey TS; Gerety G; Gumprecht J; Philis-Tsimikas A; Hansen CT; Nielsen TSS; Warren M; ;
    JAMA; 2017 Jul; 318(1):33-44. PubMed ID: 28672316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial.
    Pedersen-Bjergaard U; Agesen RM; Brøsen JMB; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen TJ; Juhl CB; Jensen AK; Lerche SS; Nørgaard K; Parving HH; Sørensen AL; Tarnow L; Thorsteinsson B
    Diabetes Obes Metab; 2022 Feb; 24(2):257-267. PubMed ID: 34643020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia.
    Brøsen JMB; Agesen RM; Kristensen PL; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen T; Stolberg CR; Juhl CB; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
    Diabetes Obes Metab; 2023 Jun; 25(6):1557-1565. PubMed ID: 36749303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycaemic Control in People with Type 2 Diabetes Treated with Insulin Degludec: A Real-World, Prospective Non-interventional Study-UPDATES Saudi Arabia.
    AlMalki MH; Aldesokey H; Alkhafaji D; Alsheikh A; Braae UC; Lehrskov LL; Magawry W; Yahia M; Haroun A
    Adv Ther; 2023 Feb; 40(2):568-584. PubMed ID: 36417058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.
    Philis-Tsimikas A; Lane W; Pedersen-Bjergaard U; Wysham C; Bardtrum L; Harring S; Heller S
    Diabetes Obes Metab; 2020 May; 22(5):779-787. PubMed ID: 31903697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).
    Pollock RF; Heller S; Pieber TR; Woo V; Gundgaard J; Hallén N; Luckevich M; Tutkunkardas D; Zinman B;
    Diabetes Obes Metab; 2019 Jul; 21(7):1706-1714. PubMed ID: 30924579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100.
    Alexopoulos AS; Andersen A; Donatsky AM; Gowda A; Buse JB
    Diabetes Obes Metab; 2021 Aug; 23(8):1983-1988. PubMed ID: 33830626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.
    DeVries JH; Bailey TS; Bhargava A; Gerety G; Gumprecht J; Heller S; Lane W; Wysham CH; Zinman B; Bak BA; Hachmann-Nielsen E; Philis-Tsimikas A
    Diabetes Obes Metab; 2019 Mar; 21(3):622-630. PubMed ID: 30362250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of major cardiovascular events, severe hypoglycaemia, and all-cause mortality for users of insulin degludec versus insulin glargine U100-A Danish cohort study.
    Jensen MH; Hejlesen O; Vestergaard P
    Diabetes Metab Res Rev; 2020 Jan; 36(1):e3225. PubMed ID: 31647163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).
    Pratley RE; Emerson SS; Franek E; Gilbert MP; Marso SP; McGuire DK; Pieber TR; Zinman B; Hansen CT; Hansen MV; Mark T; Moses AC; Buse JB;
    Diabetes Obes Metab; 2019 Jul; 21(7):1625-1633. PubMed ID: 30850995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.